Erector Spinae Block Versus PENG Block for Hip Replacement

Pain, Postoperative Clinical Trial

— PENGESP  

Official title:

Erector Spinae Block Versus PENG Block for Postoperative Analgesia After Total Hip Replacement

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05796804
• Other study ID #: 030/23
• Status: Recruiting
• Phase: N/A
• Start date: April 13, 2023
• Est. completion date: March 31, 2024

Study information

• Verified date: April 2023
• Source: Papa Giovanni XXIII Hospital
• Contact: Dario Bugada
• Phone: +393405230454
• Email: dariobugada[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

THR (Total Hip Replacement) can be very painful and regional anesthesia is very effective in reducing postoperative pain. Erector Spinae Plane Block (ESPB) and PENG (pericapsular nerve group block) are alternative approaches to the hip sensitive nerve branches that resulted to be very promising for hip surgeries. However, no studies investigated the analgesic superiority of either PENG or ESPB. In our study the investigators compare PENG (with a lateral femoral cutaneous nerve block) and ESPB in terms of pain relief expressed as morphine consumption in the first 24 hours after primary THR.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: March 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• primary total hip replacement

• informed consent

Exclusion Criteria:

• allergies to study drugs

• spinal anesthesia contraindicated

• kidney failure

• epilepsy, psychiatric disease, neurologic deficits

• revision surgery

• neuropathies in the lumbar area

• no informed consent

• pregnancy

• alcohol/opioid abuse

• emergency surgery/intensive care

Related Conditions & MeSH terms

• Pain, Postoperative

Intervention

Procedure:
• ERECTOR SPINAE PLANE BLOCK
ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
• Peng block + lateral femoral cutaneous nerve block
ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
• spinal anesthesia
bupivacaine 0.5% 2.2 ml

Locations

Country	Name	City	State
Italy	Aast Papa Giovanni Xxiii	Bergamo

Sponsors (1)

Lead Sponsor	Collaborator
Papa Giovanni XXIII Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	morphine consumption	milligrams of morphine by patient controlled analgesia intravenously	24 hours
Secondary	postoperative pain	numeric rating scale - NRS 11 point scale from 0 = "no pain" to 10 = "worst imaginable pain"	48 hours
Secondary	neuropathic pain	DN4 questionnaire - 4 items questionnaire to investigate the occurrence of neuropathic component	48 hours
Secondary	postoperative complications	nausea, vomiting, vertigo, blurred vision, syncope, bleeding, falls	48 hours
Secondary	chronic postoperative pain	numeric rating scale 11 point scale from 0 = "no pain" to 10 = "worst imaginable pain"	3 months